Approval extended

Novavax now approved for adolescents, TGA announces The Therapeutic Goods Administration (TGA) has announced it has provisionally approved the Biocelect (on behalf of Novavax) COVID-19 vaccine, Nuvaxovid, for use in individuals aged 12-17 years. The decision followed the provisional approval granted on 19 January 2022 for the use of Nuvaxovid in adults. On 9 June